We are live on !
Find out more
DMK
David M. Knott Portfolio holdings
AUM
$275M
Turnover
23.21%
1-Year Est. Return
59.23%
This Fund
S&P 500
This Quarter Est. Return
+23.53%
1 Year Est. Return
+59.23%
3 Year Est. Return
+80.95%
5 Year Est. Return
+223.18%
10 Year Est. Return
–
AUM
$221M
AUM Growth
+$50.5M
(+30%)
Cap. Flow
+$20.5M
Cap. Flow % of AUM
Cap. Flow %
9.26%
Top 10 Holdings %
Top 10 Hldgs %
55.64%
Holding
119
New
19
Increased
16
Reduced
14
Closed
9
Avg Time Held
2.9
years
Top 10 Avg Time Held
1.7
years
Top 20 Avg Time Held
1.6
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MDWT
Midwest Holding Inc. Common Stock
MDWT
|
+$8.29M |
| 2 |
Danimer Scientific, Inc.
DNMR
|
+$6.71M |
| 3 |
iPath Series B S&P 500 VIX Short-Term Futures ETN
VXX
|
+$4.06M |
| 4 |
Gilead Sciences
GILD
|
+$3.25M |
| 5 |
Eastern Bankshares
EBC
|
+$2.84M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Stericycle Inc
SRCL
|
+$10.1M |
| 2 |
LKQ Corp
LKQ
|
+$1.03M |
| 3 |
BioCryst Pharmaceuticals
BCRX
|
+$917K |
| 4 |
SBBP
Strongbridge Biopharma plc.
SBBP
|
+$781K |
| 5 |
Pfizer
PFE
|
+$701K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 36.46% |
| 2 | Financials | 19.6% |
| 3 | Materials | 10% |
| 4 | Technology | 8.95% |
| 5 | Industrials | 8.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Ligand Pharmaceuticals
LGND
$5.89B
| $24.7M | 11.16% |
397,610
| – | – |
2013 Q2
30 quarters
|
|
2
Upland Software
UPLD
$10M
| $18.7M | 8.44% |
40,650
| – | – |
2017 Q4
12 quarters
|
|
3
FTAI Aviation
FTAI
$16.9B
| $16.4M | 7.43% |
819,700
| – | – |
2020 Q2
2 quarters
|
|
4
Apollo Global Management
APO
$65.4B
| $14.7M | 6.65% |
300,000
| – | – |
2017 Q2
14 quarters
|
|
|
5
DELISTED
Danimer Scientific, Inc.
DNMR
| $11.8M | 5.32% |
+12,500
| New | +$6.71M |
2020 Q4
0 quarters
|
|
6
Alphabet (Google) Class C
GOOG
$4.12T
| $9.8M | 4.44% |
112,000
| – | – |
2019 Q1
7 quarters
|
|
7
Calumet Specialty Products
CLMT
$5.08B
| $8.28M | 3.75% |
2,645,000
+625,000
| +31% | +$2.18M |
2018 Q1
11 quarters
|
|
|
MDWT
8
DELISTED
Midwest Holding Inc. Common Stock
MDWT
| $7.7M | 3.49% |
+143,621
| New | +$8.29M |
2020 Q4
0 quarters
|
|
9
FS KKR Capital
FSK
$2.85B
| $6.54M | 2.96% |
395,175
| – | – |
2019 Q3
5 quarters
|
|
|
10
Pfizer
PFE
$169B
| $4.41M | 2% |
119,900
-19,123
| -14% | -$701K |
2013 Q2
30 quarters
|
|
|
11
LKQ Corp
LKQ
$5.62B
| $4.23M | 1.91% |
120,000
-30,000
| -20% | -$1.03M |
2018 Q2
10 quarters
|
|
12
KKR & Co
KKR
$77.4B
| $4.05M | 1.83% |
100,000
| – | – |
2020 Q1
3 quarters
|
|
|
13
Gilead Sciences
GILD
$194B
| $3.78M | 1.71% |
64,842
+53,842
| +489% | +$3.25M |
2020 Q3
1 quarter
|
|
14
DELISTED
Kennedy-Wilson Holdings
KW
| $3.76M | 1.7% |
210,000
| – | – |
2020 Q2
2 quarters
|
|
|
EIGR
15
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $3.63M | 1.64% |
9,835
+657
| +7% | +$188K |
2017 Q3
13 quarters
|
|
16
AbbVie
ABBV
$504B
| $3.51M | 1.59% |
32,769
-5,000
| -13% | -$480K |
2015 Q2
22 quarters
|
|
|
17
iPath Series B S&P 500 VIX Short-Term Futures ETN
VXX
$133M
| $3.36M | 1.52% |
+3,125
| New | +$4.06M |
2020 Q4
0 quarters
|
|
|
18
Eastern Bankshares
EBC
$4.87B
| $3.26M | 1.48% |
+200,000
| New | +$2.84M |
2020 Q4
0 quarters
|
|
19
Bristol-Myers Squibb
BMY
$122B
| $3.25M | 1.47% |
52,409
+6,000
| +13% | +$369K |
2017 Q1
15 quarters
|
|
|
HZNP
20
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $3.12M | 1.41% |
42,614
+5,083
| +14% | +$378K |
2018 Q2
10 quarters
|
|
21
Xenon Pharmaceuticals
XENE
$3.24B
| $3.08M | 1.39% |
200,000
+23,000
| +13% | +$269K |
2017 Q3
13 quarters
|
|
|
KDMN
22
DELISTED
Kadmon Holdings, Inc.
KDMN
| $2.91M | 1.32% |
702,000
+90,000
| +15% | +$355K |
2019 Q3
5 quarters
|
|
23
TG Therapeutics
TGTX
$8.26B
| $2.64M | 1.2% |
50,773
| – | – |
2020 Q2
2 quarters
|
|
|
CAP.U
24
DELISTED
Capitol Investment Corp. V Units, each consisting of one share of Class A common stock, and one-thir
CAP.U
| $2.58M | 1.17% |
+250,000
| New | +$2.55M |
2020 Q4
0 quarters
|
|
|
TRIL
25
DELISTED
Trillium Therapeutics Inc.
TRIL
| $2.57M | 1.16% |
174,699
-1,516
| -0.9% | -$21.9K |
2020 Q1
3 quarters
|
|
Similar funds
FA
KCP
HCIA
ISG
TPCM
DCM
MCL
DVC
David M. Knott's Q4 2020 Portfolio in Review
As of Q4 2020, David M. Knott held 119 positions worth $221M, up 30% from $170M the previous quarter. Its ten largest holdings account for 56% of the portfolio.
David M. Knott deployed $20.5M of net new capital in Q4 2020, opening 19 new positions and adding to 16 existing holdings. Its largest new stake was Midwest Holding Inc. Common Stock: 143,621 shares worth $7.7M.
By sector, the portfolio is most concentrated in Healthcare at 36% of assets, down from 42% a quarter earlier, followed by Financials and Materials.
On the sell side, the largest reduction was LKQ Corp, an estimated $1.03M trimmed.
- David M. Knott's largest Q4 2020 buy was Midwest Holding Inc. Common Stock: 143,621 shares worth $7.7M.
- David M. Knott added most to Gilead Sciences in Q4 2020, an estimated $3.25M increase.
- David M. Knott's biggest Q4 2020 reduction was LKQ Corp, cutting an estimated $1.03M.
- David M. Knott fully exited Stericycle Inc in Q4 2020, selling an estimated $10.1M.
- David M. Knott's ten largest holdings make up 56% of its $221M portfolio in Q4 2020.
- David M. Knott opened 19 new positions and closed 9 in Q4 2020.
- David M. Knott's portfolio value rose 30% quarter-over-quarter to $221M.
Based on David M. Knott's 13F filing for Q4 2020, filed 12 Feb 2021.